Synergistic Supplementation: How L-Carnitine and Selenium Enhance Methimazole Efficacy in Graves’ Disease

Highlights

  • Adjunctive L-carnitine and selenium (LCT/Se) therapy significantly accelerates the time to TSH-receptor antibody (TRAb) negativity (HR = 2.35).
  • Patients receiving the combined supplement required a significantly lower cumulative dose of methimazole (MMI) compared to those on monotherapy.
  • The intervention group demonstrated a markedly higher rate of spontaneous remission (OR = 11.22) over a 24-month period.
  • LCT/Se supplementation specifically mitigated symptoms of tremor, irritability, and exertional dyspnea, independent of thyroid hormone levels.

Background and Clinical Challenges in Graves’ Disease

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply